Prediction of severe acute pancreatitis: Current knowledge and novel insights

World Journal of Gastroenterology

Volumn 14, Issue 41, 2008, Pages 6273-6275

  Papachristou, Georgios I ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Acute pancreatitis; Monocyte chemotactic protein 1; Prediction; Severity

Indexed keywords

BIOLOGICAL MARKER; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 6; LEXIPAFANT; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA; AUTACOID; CCL2 PROTEIN, HUMAN; CYTOKINE; IL6 PROTEIN, HUMAN;

ACUTE PANCREATITIS; CYTOKINE RELEASE; DISEASE COURSE; DISEASE SEVERITY; EDITORIAL; ENVIRONMENTAL FACTOR; HEREDITY; HIGH RISK PATIENT; HUMAN; INFLAMMATION; MULTIPLE ORGAN FAILURE; NONHUMAN; PATHOGENESIS; PREDICTION; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; RISK ASSESSMENT; RISK FACTOR; ACUTE DISEASE; BLOOD; HOSPITALIZATION; IMMUNOLOGY; PANCREATITIS; PREDICTION AND FORECASTING;

ACUTE DISEASE; BIOLOGICAL MARKERS; CHEMOKINE CCL2; CYTOKINES; DISEASE PROGRESSION; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-1; INTERLEUKIN-6; PANCREATITIS; PREDICTIVE VALUE OF TESTS; SEVERITY OF ILLNESS INDEX; TUMOR NECROSIS FACTOR-ALPHA;

EID: 63449092936     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.14.6273     Document Type: Editorial

References (15)

1. Whitcomb DC. Clinical practice. Acute pancreatitis. N Engl J Med 2006; 354: 2142-2150
2. Steinberg WM, Schlesselman SE. Treatment of acute pancreatitis. Comparison of animal and human studies. Gastroenterology 1987; 93: 1420-1427
3. Martinez J, Sanchez-Paya J, Palazon JM, Suazo-Barahona J, Robles-Diaz G, Perez-Mateo M. Is obesity a risk factor in acute pancreatitis? A meta-analysis. Pancreatology 2004; 4: 42-48
4. Wang YL, Hu R, Lugea A, Gukovsky I, Smoot D, Gukovskaya AS, Pandol SJ. Ethanol feeding alters death signaling in the pancreas. Pancreas 2006; 32: 351-359
5. Papachristou GI, Papachristou DJ, Morinville VD, Slivka A, Whitcomb DC. Chronic alcohol consumption is a major risk factor for pancreatic necrosis in acute pancreatitis. Am J Gastroenterol 2006; 101: 2605-2610
6. Lindkvist B, Appelros S, Manjer J, Berglund G, Borgstrom A. A prospective cohort study of smoking in acute pancreatitis. Pancreatology 2008; 8: 63-70
7. Papachristou GI, Sass DA, Avula H, Lamb J, Lokshin A, Barmada MM, Slivka A, Whitcomb DC. Is the monocyte chemotactic protein-1 -2518 G allele a risk factor for severe acute pancreatitis? Clin Gastroenterol Hepatol 2005; 3: 475-481
8. Messmann H, Vogt W, Holstege A, Lock G, Heinisch A, von Furstenberg A, Leser HG, Zirngibl H, Scholmerich J. Post-ERP pancreatitis as a model for cytokine induced acute phase response in acute pancreatitis. Gut 1997; 40: 80-85
9. Chen CC, Wang SS, Lu RH, Lu CC, Chang FY, Lee SD. Early changes of serum proinflammatory and anti-inflammatory cytokines after endoscopic retrograde cholangiopancreatography. Pancreas 2003; 26: 375-380
10. Papachristou GI, Clermont G, Sharma A, Yadav D, Whitcomb DC. Risk and markers of severe acute pancreatitis. Gastroenterol Clin North Am 2007; 36: 277-296, viii
11. Malleo G, Mazzon E, Siriwardena AK, Cuzzocrea S. Role of tumor necrosis factor-alpha in acute pancreatitis: from biological basis to clinical evidence. Shock 2007; 28: 130-140
12. Chen CJ, Kono H, Golenbock D, Reed G, Akira S, Rock KL. Identification of a key pathway required for the sterile inflammatory response triggered by dying cells. Nat Med 2007; 13: 851-856
13. Denham W, Yang J, Fink G, Denham D, Carter G, Bowers V, Norman J. TNF but not IL-1 decreases pancreatic acinar cell survival without affecting exocrine function: a study in the perfused human pancreas. J Surg Res 1998; 74: 3-7
14. Rau B, Baumgart K, Kruger CM, Schilling M, Beger HG. CC-chemokine activation in acute pancreatitis: enhanced release of monocyte chemoattractant protein-1 in patients with local and systemic complications. Intensive Care Med 2003; 29: 622-629
15. Johnson CD, Kingsnorth AN, Imrie CW, McMahon MJ, Neoptolemos JP, McKay C, Toh SK, Skaife P, Leeder PC, Wilson P, Larvin M, Curtis LD. Double blind, randomised, placebo controlled study of a platelet activating factor antagonist, lexipafant, in the treatment and prevention of organ failure in predicted severe acute pancreatitis. Gut 2001; 48: 62-69